EVGN Jun 2024 2.500 call
- PR Newswire
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced encouraging initial findings from an ongoing Phase 1 clinical trial. In the study, Biomica is investigating the safety and tolerability of its microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, an anti-PD1 immune checkpoint inhibitor, in patients with non-small cell lung cancer (N
- PR Newswire
Evogene Reports First Quarter 2024 Financial Results
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the first quarter period ended March 31, 2024.
- PR Newswire
Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds
Casterra Ag Ltd., an integrated solutions company for growing castor for bio-based industrial applications, such as biofuels & biopolymers and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced it has recently signed new agreements with both existing and new seed producers in Africa. These agreements are anticipated to bolster Casterra's seed supply capabilities with an addition of approximately 500 tons of high-yielding, high-oil castor seeds. This new addition, together with p
